UCSD

Airway Research Center

Specializing in COPD & ASTHMA right 2006 U

 

Home
Current Studies
About Us
Amer Lung Assoc
What's New!
Web Links & Articles

Asthma Studies

Study ClinicalTrial.gov Link

Study of Soy Isoflavones in Asthma (SOYA) Now Enrolling - Recent advances in asthma research suggest there is a link between nutrition and asthma.  The purpose of this study is to find out if soy isoflavones (chemicals found in soybeans) improve lung function and reduce asthma symptoms in patients with poorly controlled asthma. The soy isoflavone supplement, Novasoy®, used in this study is investigational.  The word “investigational” means Novasoy® is not approved by the U. S. Food and Drug Administration (FDA) for the treatment of asthma and is still being tested in research studies.  However, the FDA is allowing the use of Novasoy® in this study.

CT Link
Study of Asthma and Nasal Steroids (STAN): This study will be a randomized, double-masked, placebo-controlled trial of the effectiveness of nasal steroids for the treatment of chronic rhinitis and sinusitis on asthma control (6 months of nasal steroid
(mometasone), or placebo).


CT Link

Cephalon 3083 Study: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (18-75 Years of Age) With Eosinophilic Asthma

CT Link

Sanofi-Aventis ACT11457 Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously (SC) Once Weekly for 12 Weeks in Patients with Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid (ICS) Plus Long-Acting Beta2 Agonist (LABA) Therapy

CT Link

GlaxoSmithKline FFA110245 Study:  A randomized, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of fluticasone furoate inhalation powder in the treatment of persistent asthma in adults and adolescents. (25-weeks)

CT Link
Analysis of Biomarkers Now Enrolling - In peripheral mononuclear blood cells (PBMC) and INDUCED SPUTUM (IS) SPECIMENS OF ASTHMA PATIENTS AND NORMAL INDIVIDUAL. Joe W. Ramsdell, M.D. and his colleagues are conducting research to determine how easy it might be to measure chemicals in sputum and blood that might show indications of irritation of the airways.   These samples will be collected from asthmatics and healthy control subjects. Approximately 60 participants will be asked to take part in this research study at this site. Dr. Ramsdell is conducting this research study with Johnson & Johnson, the sponsor of this study. This is a one visit study taking 2 to 3 hours.  
   
Back to Top

COPD Studies

Study ClinicalTrial.gov Link
COPDGene Now Enrolling - The University of California, San Diego Clinical Trials & Airway Research Center is particapating in a National study to find out more about the genetic causes of COPD. CT Link

NOVARTIS CQVA149A2304 STUDY: A 64-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD). 

CT Link

GlaxoSmithKline DB2113361 Study: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease

CT Link

GlaxoSmithKline HZC113782 Study: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at risk for cardiovascular disease. (12-months)

CT Link

Forest LAC-MD-32 Study: A Long-Term (52-week), Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate compared with Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

CT Link
Back to Top